{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T15:10:35Z","timestamp":1718550635569},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,12,11]],"date-time":"2003-12-11T00:00:00Z","timestamp":1071100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2004,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The majority of men with advanced prostate cancer (PCa) respond to androgen deprivation therapy (ADT) with objective evidence of tumor regression. However, these tumors will regrow in the presence of low\u2010androgen levels after 12\u201318 months. Regrowth after ADT is associated with upregulation of growth factor (GF) mediated pathways. The compound farnesylthiosalicylate (FTS), a specific antagonist of the 21 kDa Ras protein, suppresses GF signaling and it might be a useful therapy against advanced PCa.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>We measured androgen and GF dependent growth of androgen dependent LNCaP and androgen hypersensitive CWR\u2010R1 PCa cells in response to specific inhibitors of GF pathways, including FTS. Inhibition of GF mediated signaling and cell\u2010cycle pathways was confirmed by Western blotting of extracts from treated cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Both LNCaP and CWR\u2010R1 cells were dependent on GF signaling pathways for cell growth. FTS, as well as suppressing cell growth, inhibited GF signaling pathway activity and reduced the levels of E2F1, p\u2010Rb, and p\u2010cdc2, all GF dependent mediators of cell\u2010cycle progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>These data suggest that FTS might be a useful agent against PCa that has relapsed after ADT. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.10336","type":"journal-article","created":{"date-parts":[[2004,2,12]],"date-time":"2004-02-12T09:01:08Z","timestamp":1076576468000},"page":"325-334","source":"Crossref","is-referenced-by-count":14,"title":["The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro"],"prefix":"10.1002","volume":"58","author":[{"given":"Robert A.","family":"McPherson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark C.","family":"Conaway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris W.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Santen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,12,11]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01246-8"},{"key":"e_1_2_1_3_2","volume-title":"Williams textbook of endocrinology","author":"Santen RJ","year":"2002"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s003450000186"},{"key":"e_1_2_1_5_2","first-page":"5718","article-title":"Androgen receptor expression in androgen\u2010independent prostate cancer is associated with increased expression of androgen\u2010regulated genes","volume":"58","author":"Gregory CW","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9896(200007)191:3<227::AID-PATH636>3.0.CO;2-3"},{"key":"e_1_2_1_8_2","first-page":"279","article-title":"Activation of mitogen\u2010activated protein kinase associated with prostate cancer progression","volume":"59","author":"Gioeli D","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68354-1"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01253-5"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.20.5406"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201656"},{"key":"e_1_2_1_13_2","first-page":"1168","article-title":"Immunohistochemical demonstration of phospho\u2010akt in high Gleason grade prostate cancer","volume":"8","author":"Malik SN","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_14_2","first-page":"4291","article-title":"Loss of PTEN expression in paraffin\u2010embedded primary prostate cancer correlates with high Gleason score and advanced stage","volume":"59","author":"McMenamin ME","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7716512"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204950"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.12.2121"},{"key":"e_1_2_1_18_2","first-page":"1809","article-title":"LNCaP model of human prostatic carcinoma","volume":"43","author":"Horoszewicz JS","year":"1983","journal-title":"Cancer Res"},{"key":"e_1_2_1_19_2","first-page":"3042","article-title":"CWR22: The first human prostate cancer xenograft with strongly androgen\u2010dependent and relapsed strains both in vivo and in soft agar","volume":"56","author":"Nagabhushan M","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.10.2918"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202730"},{"key":"e_1_2_1_22_2","first-page":"1449","article-title":"Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3\u2032\u2010kinase and Akt\/protein kinase B","volume":"59","author":"Carson JP","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(01)00189-3"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/10.7.699"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/387422a0"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1991.tb04896.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202602"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.24.14019"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001099900052"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990315)80:6<911::AID-IJC18>3.0.CO;2-4"},{"key":"e_1_2_1_31_2","first-page":"555","article-title":"The Ras inhibitor S\u2010trans,trans\u2010farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance","volume":"8","author":"Gana\u2010Weisz M","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7701328"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.31.22033"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)61714-2"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505253322101"},{"key":"e_1_2_1_36_2","first-page":"1273","article-title":"Collocation of androgen receptor gene mutations in prostate cancer","volume":"7","author":"Buchanan G","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1210\/mend.11.4.9906"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.813200"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1367-5931(97)80010-5"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.10336","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.10336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T19:00:35Z","timestamp":1700161235000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.10336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,11]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1002\/pros.10336"],"URL":"https:\/\/doi.org\/10.1002\/pros.10336","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,11]]}}}